Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 15,923 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 2 Clear all
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

NCT00401375
View directory record Official record
Conditions
Post-Operative Ileus (POI)
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01562275
View directory record Official record
Conditions
Neoplasms
Interventions
Ipatasertib, Cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

NCT05746481
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367
View directory record Official record
Conditions
Hypertension
Interventions
BMS-823778, Placebo matching with BMS-823778
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
22
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

NCT01453400
View directory record Official record
Conditions
Pharyngitis
Interventions
Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo, Acetaminophen + placebo, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

Robot Aided Rehabilitation - Intervention

NCT02359253
View directory record Official record
Conditions
Stroke
Interventions
Passive stretching, Passive movement, IntelliArm, Hand robot
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837
View directory record Official record
Conditions
Hemophilia A
Interventions
Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Davis, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rethinking Eating and FITness for Men

NCT01843595
View directory record Official record
Conditions
Weight Loss, Overweight
Interventions
REFIT Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 23, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06632977
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
Other · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
108
States / cities
Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Microbial Associations in Periodontal Health and Disease

NCT00066001
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases
Interventions
metronidazole
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
35 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 23, 2026, 6:54 AM EDT
Terminated Not applicable Interventional Results available

A Clinical Trial to Evaluate the Safety and Effectiveness of the Raindrop Near Vision Inlay for Pseudophakic Subjects

NCT03017612
View directory record Official record
Conditions
Presbyopia
Interventions
Raindrop Near Vision Inlay
Device
Lead sponsor
ReVision Optics, Inc.
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Laguna Hills, California • Orange, California • Bloomington, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 23, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

NCT05733767
View directory record Official record
Conditions
Cardiopulmonary Disease, Smoking Cessation, Inpatient
Interventions
Enhanced Usual Care (EUC), Nurse Practitioner Tobacco Treatment Team (NPT3)
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing a Shortened Version of the AlAn's Game

NCT03834467
View directory record Official record
Conditions
Psychopathic Personality Trait
Interventions
Arm 1 - Elevation Stimulus Video, Arm 2 - Control Stimulus Video
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years
Enrollment
537 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 23, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

NCT03948867
View directory record Official record
Conditions
Sickle Cell Anemia in Children
Interventions
Hydroxyurea, Elevated Arm TCD Examination, Normal Arm TCD Examination
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 16 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 23, 2026, 6:54 AM EDT
Withdrawn Not applicable Interventional

The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

NCT00656331
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine and Hydrocholorothiazide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

NCT02715531
View directory record Official record
Conditions
Solid Tumor
Interventions
5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 23, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional Results available

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
AMG 420
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Park Ridge, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 6:54 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

NCT06882772
View directory record Official record
Conditions
Congenital Heart Disease (CHD)
Interventions
2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
1 Month to 3 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

NCT07286175
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Orange, California • New Haven, Connecticut • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 6:54 AM EDT